Amyloid fibril formation of α-synuclein (αS) is associated with multiple neurodegenerative diseases, including Parkinson’s disease (PD). Growing evidence suggests that progression of PD is linked to ...

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

Researchers have used computational models to understand what drives the accumulation of alpha-synuclein protein, a key culprit in the development of Parkinson’s disease. The study, published today as ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...

A small new trial published in the journal Nature Medicine describes what would be two firsts for Parkinson's disease, if they pan out: a diagnostic test and a potential immune-based treatment that ...

Researchers have used computational models to understand what drives the accumulation of alpha-synuclein protein, a key culprit in the development of Parkinson's disease. Researchers have used ...

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson ...